Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study

Advances in Therapy

Volumn 33, Issue 1, 2016, Pages 46-57

  Branco, Jaime C ^a   Barcelos, Anabela ^c   de Araújo, Filipe Pombo ^b   Sequeira, Graça ^e   Cunha, Inês ^c   Patto, José Vaz ^f   Oliveira, Margarida ^g   Mateus, Margarida Pratas ^b   Couto, Maura ^h   Nero, Patrícia ^b   Pinto, Patrícia ^d   Monteiro, Paulo ^h   Castelão, Walter ^b   Félix, Jorge ⁱ   Ferreira, Diana ⁱ   Almeida, João ⁱ   Silva, Maria João ⁱ  

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL EGAS MONIZ   (Portugal)

^c Hospital Infante D Pedro EPE   (Portugal)

^d CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^e HOSPITAL DE FARO   (Portugal)

^f INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

^g EPE Vila Nova de Gaia   (Portugal)

^h Centro Hospitalar Tondela Viseu   (Portugal)

ⁱ Exigo Consultores   (Portugal)

Author keywords

Continuation rates; Methotrexate; Methotrexate failure; Oral treatment; Rheumatoid arthritis; Subcutaneous methotrexate; Subcutaneous treatment; Treatment duration; UMAR

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALAISE; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NAUSEA; PREGNANCY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STOMACH DISEASE; SURVIVAL; TREATMENT DURATION; VOMITING; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84957442641     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0276-3     Document Type: Article

References (26)

1. ACRSRAG: American College of Rheumatology Subcommittee on rheumatoid arthritis guidelines. Guidelines for the management of rheumatoid arthritis—2002 update. Arthritis Rheum. 2002;46(2):328–46.
2. Smolen JS, Landewé R, Breedveld F, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
3. Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicentre, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73–81.
4. Krüger K, Wollenhaupt J, Albrecht K, et al. German guidelines for the sequential medical treatment of rheumatoid arthritis 2012: adapted EULAR recommendations and update of a treatment algorithm [S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2012: adaptierte EULAR Empfehlung und aktualisierter Therapiealgorithmus]. Z Rheumatol. 2012;71(7):592–603.
5. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549–51.
6. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63(10):1232–4.
7. Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559–82.
8. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
9. Fonseca JE, Bernardes M, Canhao H, et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis—October 2011 update. Acta Reumatol Port. 2011;36(4):385–8.
10. Akaike H. Information theory as an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors. 2nd international symposium on information theory. Budapest: Akademiai Kiado; 1973. p. 276–81.
11. Striesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskel Dis. 2012;4(1):3–9.
12. Braun J. Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskel Dis. 2011;3(3):151–8.
13. Breedveld FC, Weisman MH, Kavanaugh AF, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
14. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62(1):33–43.
15. Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol. 2002;29(10):2077–83.
16. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 1999;42(7):1322–8.
17. Shiroky JB, Watts CS, Neville C. Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations. Arthritis Rheum. 1989;32(9):1160–4.
18. Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia. 2009;47:207–11.
19. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–93.
20. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology. 2005;44:61–6.
21. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163–72.
22. Genovese, MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443–50.
23. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986;29(7):822–31.
24. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–7.
25. Rau R, Simianer S, van Riel PL, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol. 2004;33(3):145–53.
26. Neves C, Jorge R, Barcelos A. A teia de toxicidade do metotrexato. Acta Reumatol Port. 2009;34:11–34.